Meningococcal Disease
A rapidly progressive infection caused by Neisseria meningitidis bacteria, most often presenting as meningitis or bloodstream infection.
What causes Meningococcal Disease?
Meningococcal disease is caused by Neisseria meningitidis. The bacteria spread through prolonged or close contact with respiratory and throat secretions, including kissing or living in the same household.
Symptoms and what to notice
Sudden fever, severe headache, stiff neck, nausea, vomiting, light sensitivity, confusion, extreme sleepiness, rapid breathing, cold hands and feet, severe aches, or a dark purple rash. Infants may be irritable, feed poorly, or have a bulging fontanelle.
How long can it last?
Symptoms can worsen within hours. Incubation is usually 3 to 4 days but ranges roughly 1 to 10 days. Recovery may take weeks, and survivors can have permanent complications.
How serious is Meningococcal Disease?
This is a medical emergency. Even with treatment, illness can cause shock, limb loss, hearing loss, brain injury, kidney damage, or death. Close contacts may need preventive antibiotics quickly.
Treatment and management
Immediate hospital treatment with intravenous antibiotics such as ceftriaxone or cefotaxime is required. Supportive care may include fluids, blood-pressure support, respiratory care, and treatment of clotting or organ failure. Public health identifies contacts needing prophylaxis.
Vaccine: who and when?
U.S. products include Menveo and MenQuadfi (MenACWY); Bexsero and Trumenba (MenB); and pentavalent Penbraya and Penmenvy (MenABCWY). Routine adolescent MenACWY is given at ages 11-12 with a booster at 16. MenB or MenABCWY use depends on age, risk, shared decision-making, and using compatible products.
Cost note: Patient cost varies by product, provider, insurance, location, and eligibility. Many recommended vaccines are covered in network without cost sharing, and qualifying children may use the Vaccines for Children program.
Trusted source
Patient cost varies by insurance, provider, location, and eligibility. Coverage and public-health access differ, so listed prices are examples rather than guaranteed patient prices. This page is for general education and does not replace individualized medical advice, diagnosis, vaccination assessment, or treatment.
Meningococcal Disease: Symptoms, Causes, Treatment, Prevention, and Vaccine Information
Meningococcal disease is uncommon but feared because a healthy person can become critically ill in a single day. Infection most often appears as meningitis or meningococcemia, a bloodstream infection that can produce shock and widespread tissue damage. Fast recognition and antibiotics save lives; vaccination and preventive treatment of close contacts reduce additional cases.
Important: This page is for general education. It does not replace diagnosis, treatment, vaccination advice, or emergency care from a qualified healthcare professional.
Quick Facts
| Topic | Current information |
|---|---|
| Cause | Meningococcal disease is caused by Neisseria meningitidis. The bacteria spread through prolonged or close contact with respiratory and throat secretions, including kissing or living in the same household. |
| Main symptoms | Sudden fever, severe headache, stiff neck, nausea, vomiting, light sensitivity, confusion, extreme sleepiness, rapid breathing, cold hands and feet, severe aches, or a dark purple rash. Infants may be irritable, feed poorly, or have a bulging fontanelle. |
| Typical course | Symptoms can worsen within hours. Incubation is usually 3 to 4 days but ranges roughly 1 to 10 days. Recovery may take weeks, and survivors can have permanent complications. |
| Treatment | Immediate hospital treatment with intravenous antibiotics such as ceftriaxone or cefotaxime is required. Supportive care may include fluids, blood-pressure support, respiratory care, and treatment of clotting or organ failure. Public health identifies contacts needing prophylaxis. |
| Vaccine status | U.S. products include Menveo and MenQuadfi (MenACWY); Bexsero and Trumenba (MenB); and pentavalent Penbraya and Penmenvy (MenABCWY). Routine adolescent MenACWY is given at ages 11-12 with a booster at 16. MenB or MenABCWY use depends on age, risk, shared decision-making, and using compatible products. |
History and Public-Health Importance
Outbreaks in military barracks, college dormitories, and communities led to progressively broader vaccines. Modern U.S. vaccination targets serogroups A, C, W, Y, and B with separate quadrivalent, serogroup B, or pentavalent products. Surveillance tracks serogroups and vaccine effectiveness so recommendations can adapt as disease patterns change.
What Causes Meningococcal Disease?
Meningococcal disease is caused by Neisseria meningitidis. The bacteria spread through prolonged or close contact with respiratory and throat secretions, including kissing or living in the same household.
Many people temporarily carry meningococci in the nose or throat without illness. Transmission usually requires close or lengthy contact with saliva or respiratory secretions; it is not as easily spread as a cold. Household members, childcare contacts, and people directly exposed to oral secretions may qualify for prompt antibiotic prophylaxis regardless of vaccination status.
Symptoms and Typical Course
Sudden fever, severe headache, stiff neck, nausea, vomiting, light sensitivity, confusion, extreme sleepiness, rapid breathing, cold hands and feet, severe aches, or a dark purple rash. Infants may be irritable, feed poorly, or have a bulging fontanelle.
Meningitis typically causes fever, headache, stiff neck, vomiting, light sensitivity, and altered mental status. Bloodstream infection can begin with fever, fatigue, vomiting, diarrhea, severe limb pain, rapid breathing, cold extremities, and a non-blanching rash. Infants can lack the classic stiff neck. Deterioration can be extremely rapid.
Complications and Who Is at Higher Risk
This is a medical emergency. Even with treatment, illness can cause shock, limb loss, hearing loss, brain injury, kidney damage, or death. Close contacts may need preventive antibiotics quickly.
Septic shock, disseminated clotting, adrenal injury, brain swelling, seizures, hearing loss, neurologic disability, scarring, and amputation can occur. People without a functioning spleen, with complement deficiencies or complement-inhibitor treatment, microbiologists exposed to the organism, travelers to certain regions, and outbreak populations have elevated risk.
How It Is Diagnosed
Blood or cerebrospinal-fluid culture and molecular testing identify the organism. Antibiotics must not wait for lumbar puncture or final laboratory confirmation when clinical suspicion is high. Isolates and specimens may be sent to public-health laboratories for serogroup and outbreak investigation.
Treatment and Recovery
Immediate hospital treatment with intravenous antibiotics such as ceftriaxone or cefotaxime is required. Supportive care may include fluids, blood-pressure support, respiratory care, and treatment of clotting or organ failure. Public health identifies contacts needing prophylaxis.
Ceftriaxone or cefotaxime is typical empiric therapy, adjusted when susceptibility and clinical context are known. Patients require droplet precautions early in treatment. Rifampin, ciprofloxacin, ceftriaxone, or another recommended agent may be used for close-contact prophylaxis depending on resistance, pregnancy, age, and local public-health advice.
Vaccine Information
U.S. products include Menveo and MenQuadfi (MenACWY); Bexsero and Trumenba (MenB); and pentavalent Penbraya and Penmenvy (MenABCWY). Routine adolescent MenACWY is given at ages 11-12 with a booster at 16. MenB or MenABCWY use depends on age, risk, shared decision-making, and using compatible products.
Menveo and MenQuadfi protect against A, C, W, and Y. Bexsero and Trumenba protect against B and are not interchangeable within a series. Penbraya pairs MenQuadfi-type coverage with Trumenba components, while Penmenvy pairs Menveo-type coverage with Bexsero components. Pentavalent vaccine is used only when both MenACWY and MenB vaccination are indicated at the same visit. People with ongoing medical or occupational risk need schedules and boosters tailored to that risk.
Prevention
Receive recommended adolescent and risk-based vaccines, do not share items contaminated with saliva during outbreaks, and promptly complete contact prophylaxis when public health advises it. Vaccination does not replace antibiotics for a qualifying close exposure.
When to Seek Medical Care
Call emergency services for sudden fever with stiff neck, confusion, purple rash, severe limb pain, cold hands and feet, rapid breathing, or rapidly worsening illness. Do not wait for every classic symptom.
Frequently Asked Questions
Is meningococcal disease the same as meningitis?
It can cause meningitis, but it can also cause bloodstream infection, pneumonia, joint infection, and other invasive disease.
Do all contacts need antibiotics?
No. Public health identifies close contacts with meaningful secretion exposure; casual contacts usually do not need prophylaxis.
Why are there several vaccines?
Different products cover different meningococcal serogroups. Age, medical risk, outbreak status, and prior products determine the schedule.
Can disease progress quickly?
Yes. Severe infection can worsen within hours, so emergency evaluation is essential.
Key Takeaway
Meningococcal disease is a time-critical emergency. Recognize rapid symptoms, start antibiotics immediately, protect close contacts, and use the correct age- and risk-specific vaccines.
Medical, treatment, and vaccine information was reviewed against official U.S. public-health guidance available through September 2026.